Mattr: Early Stage Turnaround Poised For Strong Growth And Re-Rating (TSX:MATR:CA)

MATR’s wires are used in nuclear reactors. Low tolerance for failure. Monty Rakusen/DigitalVision via Getty Images Mattr Corp: High Quality Industrial Trading at < 5x EBITDA Investment Thesis Mattr Corp. (TSX:MATR:CA) (OTCPK:MTTRF) stands as a prime investment opportunity, underpinned by its transformation from a hyper cyclical business into a diversified industrial powerhouse focusing on less…

Read More

CK Asset: Too Early To Be Bullish (OTCPK:CHKGF)

Nikada Elevator Pitch CK Asset Holdings Limited (OTCPK:CHKGF) [1113:HK] is rated as a Hold. On its corporate website, CK Asset calls itself a “multinational conglomerate” that is “one of the largest property developers in Hong Kong.” With my previous write-up published on June 29, 2021, I touched on CK Asset’s capital allocation moves in terms…

Read More

Dino Polska: A Compounder On Early Stages (OTCMKTS:DNOPY)

andresr Founded in 1999 by Tomasz Biernacki (current CEO at just 50 years old), Dino Polska (OTCPK:DNOPY) is the fastest-growing Polish retailer in the country. The business model has several peculiarities that set it apart from the competition. With a market capitalization of PLN 45.27 billion, it is a company with significant expansion potential, operating…

Read More

These Are Your Top-Performing ETFs In Early 2024

By Andrew Prochnow Following a robust beginning to the trading year of 2024, the ETF landscape has witnessed numerous offerings delivering notable returns during the initial months of the year. Unsurprisingly, the technology sector has emerged as one of the standout performers, with semiconductor stocks leading the charge. However, it’s worth noting that AI-focused semiconductor…

Read More

Prelude Therapeutics Stock: Interesting Pipeline But Too Early To Buy (PRLD)

peterschreiber.media/iStock via Getty Images Topline Summary Prelude Therapeutics Incorporated (NASDAQ:PRLD) is a clinical-stage biopharma developing targeted therapies across a range of different cancers. They have 3 drugs currently in clinical testing, although all of these remain at phase 1 at this time. I have no major concerns about their current cash position, although it might…

Read More

My Top Insurance Picks In Early 2024

akinbostanci Long ago, Warren Buffett made me enthusiastic about the insurance industry and it has remained my biggest allocation. Insurance companies are not popular on SA except for Berkshire Hathaway (BRK.A) (BRK.B). They appear boring to many readers, one can hardly expect fireworks from them, and accounting is a must to understand an insurer. But…

Read More

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position (COYA)

BlackJack3D Coya Therapeutics (NASDAQ:COYA) targets inflammation by modulating the function of regulatory T cells (Tregs) in neurological diseases. The “original” lead asset used to be COYA 101, an autologous regulatory T-cell product candidate with a completed Phase 2a trial in Amyotrophic Lateral Sclerosis under its belt. The trial was completed way back in 2022. However,…

Read More

Carisma Therapeutics: New Frontiers In Cell Therapy, But Too Early To Buy In (NASDAQ:CARM)

ffikretow Topline Summary Carisma Therapeutics (NASDAQ:CARM), formerly Sesen Bio, is a developmental biotech exploring the potential of cell therapies for cancer management. They hope that by exploiting immune cells called macrophages that they can continue to push the field of cell therapies forward. But cash concerns and limited clinical trial data make this something difficult…

Read More

QQQY: Too Early To Call On This New And Untested Strategy

gopixa Thesis The Defiance Nasdaq 100 Enhanced Options Income ETF (NASDAQ:QQQY) is a new ETF launched to offer income generation and possible capital appreciation, with a strategy focusing on the selling of at-the-money options. The income generation comes from the options premium collected but can have negative impacts from movements in the underlying index. The…

Read More

Lexicon Pharma: Inpefa’s Early Clinical Benefits, Rehospitalization Data May Unlock Value

apomares/E+ via Getty Images Introduction & Thesis Shares of biopharma Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) are ~60% off their May highs, despite holding an FDA-approved key drug (Inpefa) for heart failure in its portfolio. The sell-off is largely attributed to investor concerns over Inpefa’s market uptake amid a perfect storm of competition from pharma heavyweights like…

Read More

Shattuck Labs: Early Positive Data May Be A Harbinger Of Good Things (NASDAQ:STTK)

koto_feja/E+ via Getty Images Shattuck Labs (NASDAQ:STTK) develops bi-functional fusion proteins targeting cancer and autoimmune diseases. Shattuck’s ARC (Agonist Redirected Checkpoint) platform seamlessly integrates checkpoint inhibition with TNF costimulation. The platform has generated over 400 preclinical bi-functional fusion protein drug candidates. The primary clinical-stage product, SL-172154 (SIRPα-Fc-CD40L), is currently undergoing two Phase 1 clinical trials….

Read More

Janux Therapeutics: Precision Immunotherapy, But Overpriced For Such An Early Stage (NASDAQ:JANX)

Bussarin Rinchumrus Topline Summary Janux Therapeutics (NASDAQ:JANX) is a biotech focused on developing novel immunotherapeutic approaches for patients with cancer. Using a unique T-cell engaging approach, the company hopes to avoid some of the issues that have faced the main players in multi-specific antibody development, particularly relating to toxicity and pharmacodynamics. While they have cash…

Read More

Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash (NASDAQ:WVE)

anusorn nakdee/iStock via Getty Images Wave Life Sciences Ltd. (NASDAQ:WVE) develops stereopure oligonucleotides using its PRISM platform to target disease-causing genetic mutations. This is its pipeline: WVE PIPELINE (WVE WEBSITE) Lead assets are WVE-N531 targeting exon 53 skipping DMD, and WVE-003 targeting Huntington’s Disease in phase 1/2 trials. WVE owns the first molecule globally, while…

Read More

Early US Q3 GDP Nowcasts Point To Ongoing Economic Growth

Lemon_tm Recession forecasts continue to swirl in some corners of the economics profession, but early econometric estimates for third-quarter GDP data suggest that the expansion will persist for now. US output for the July-through-September period is expected to rise 2.0% for GDP’s seasonally adjusted annualized change, based on the median estimate via several sources compiled…

Read More